Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M S Soloway

Showing results (301-310 of 307) with videos related to

Pageof 31
Sort By:
You have reached the last page of results.This site can display upto 307 results.
The Journal of Urology|August 1, 1996
Use of a new tumor marker, urinary NMP22, in the detection of occult or rapidly recurring transitional cell carcinoma of the urinary tract following surgical treatmentM S Soloway, V Briggman, G A Carpinito, et al.
The Journal of Urology|October 1, 1996
Urinary nuclear matrix protein as a marker for transitional cell carcinoma of the urinary tractG A Carpinito, W M Stadler, J V Briggman, et al.
The Journal of Urology|January 1, 1983
A comparison of estramustine phosphate versus cis-platinum alone versus estramustine phosphate plus cis-platinum in patients with advanced hormone refractory prostate cancer who had had extensive irradiation to the pelvis or lumbosacral areaM S Soloway, S Beckley, M F Brady, et al.
Cancer|April 1, 1983
Treatment of newly diagnosed metastatic prostate cancer patients with chemotherapy agents in combination with hormones versus hormones aloneG P Murphy, S Beckley, M F Brady, et al.
The Journal of Urology|May 1, 1983
Comparison of estramustine phosphate, methotrexate and cis-platinum in patients with advanced, hormone refractory prostate cancerS A Loening, S Beckley, M F Brady, et al.
Journal of Surgical Oncology|June 1, 1983
The addition of chemotherapy to hormonal therapy for treatment of patients with metastatic carcinoma of the prostateR P Gibbons, S Beckley, M F Brady, et al.
Urology|September 25, 1997
Improved detection of recurrent bladder cancer using the Bard BTA stat TestM F Sarosdy, M A Hudson, W J Ellis, et al.
Pageof 31

Showing results (301-310 of 307) with videos related to

Sort By:
Pageof 31
You have reached the last page of results.This site can display upto 307 results.
The Journal of Urology|August 1, 1996
Use of a new tumor marker, urinary NMP22, in the detection of occult or rapidly recurring transitional cell carcinoma of the urinary tract following surgical treatmentM S Soloway, V Briggman, G A Carpinito, et al.
The Journal of Urology|October 1, 1996
Urinary nuclear matrix protein as a marker for transitional cell carcinoma of the urinary tractG A Carpinito, W M Stadler, J V Briggman, et al.
The Journal of Urology|January 1, 1983
A comparison of estramustine phosphate versus cis-platinum alone versus estramustine phosphate plus cis-platinum in patients with advanced hormone refractory prostate cancer who had had extensive irradiation to the pelvis or lumbosacral areaM S Soloway, S Beckley, M F Brady, et al.
Cancer|April 1, 1983
Treatment of newly diagnosed metastatic prostate cancer patients with chemotherapy agents in combination with hormones versus hormones aloneG P Murphy, S Beckley, M F Brady, et al.
The Journal of Urology|May 1, 1983
Comparison of estramustine phosphate, methotrexate and cis-platinum in patients with advanced, hormone refractory prostate cancerS A Loening, S Beckley, M F Brady, et al.
Journal of Surgical Oncology|June 1, 1983
The addition of chemotherapy to hormonal therapy for treatment of patients with metastatic carcinoma of the prostateR P Gibbons, S Beckley, M F Brady, et al.
Urology|September 25, 1997
Improved detection of recurrent bladder cancer using the Bard BTA stat TestM F Sarosdy, M A Hudson, W J Ellis, et al.
Pageof 31